Suppr超能文献

减低强度预处理的干细胞移植:双脐血与无关供者移植的比较。

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.

机构信息

Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

出版信息

Biol Blood Marrow Transplant. 2012 May;18(5):805-12. doi: 10.1016/j.bbmt.2011.10.016. Epub 2011 Oct 19.

Abstract

There are little data comparing umbilical cord blood (UBC) and conventional stem cell sources for reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis of RIC HCST using double UCB (dUCB) grafts and RIC HSCT using unrelated donor (URD) grafts. The study included 64 dUCB transplantations and 221 URD transplantations performed at Dana-Farber Cancer Institute and Massachusetts General Hospital between 2004 and 2008. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 14.1% for dUCB and 20.3% for URD (P = .32). The 2-year cumulative incidence of chronic GVHD was significantly lower in dUCB compared with URD (21.9% versus 53.9%; P < .0001). The 2-year cumulative incidence of nonrelapse mortality was significantly higher in dUCB (26.9% versus 10.4%; P = .0009). In our analysis, dUCB HSCT and URD HSCT had comparable 3-year overall survival (46% in dUCB and 50% in URD; P = .49) and progression-free survival (30% in dUCB and 40% in URD; P = .47). dUCBT was associated with greater nonrelapse mortality despite less chronic GVHD. Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable alternative for patients undergoing RIC HSCT without an HLA-matched donor.

摘要

对于接受低强度预处理条件(RIC)的造血干细胞移植(HSCT),脐血(UBC)和传统干细胞来源的数据对比很少。我们对使用双份 UBC(dUCB)移植物的 RIC-HSCT 和使用非血缘供体(URD)移植物的 RIC-HSCT 进行了回顾性分析。这项研究包括了 2004 年至 2008 年期间在 Dana-Farber 癌症研究所和马萨诸塞州综合医院进行的 64 例 dUCB 移植和 221 例 URD 移植。dUCB 的 II-IV 级急性移植物抗宿主病(GVHD)累积发生率为 14.1%,URD 的为 20.3%(P =.32)。与 URD 相比,dUCB 的慢性 GVHD 2 年累积发生率明显较低(21.9%对 53.9%;P <.0001)。dUCB 的 2 年非复发死亡率明显高于 URD(26.9%对 10.4%;P =.0009)。在我们的分析中,dUCB-HSCT 和 URD-HSCT 的 3 年总生存率(dUCB 为 46%,URD 为 50%;P =.49)和无进展生存率(dUCB 为 30%,URD 为 40%;P =.47)无显著差异。尽管慢性 GVHD 较少,但 dUCBT 与较高的非复发死亡率相关。我们的研究结果表明,对于没有 HLA 匹配供体的接受 RIC-HSCT 的患者,使用 2 份部分匹配的 UCB 单位似乎是一种合适的替代方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验